Vaginal atrophy happens when the vaginal walls become thinner, drier, and less elastic, most often because of declining estrogen levels. It affects roughly 40% to 54% of postmenopausal women with bothersome symptoms, though the true range in studies spans 27% to 84% depending on how it’s measured. Menopause is the most common trigger, but it’s far from the only one.
How Estrogen Keeps Vaginal Tissue Healthy
Estrogen is the hormone most responsible for maintaining vaginal tissue. It stimulates collagen production in the vaginal wall, and collagen (particularly types I and III) provides the structural support and tensile strength that keeps tissue firm yet flexible. Connective tissue in the vagina remodels continuously throughout the reproductive years, a process that depends heavily on estrogen signaling. When estrogen drops, collagen production slows and the tissue gradually loses both thickness and resilience.
Estrogen also supports blood flow to the vaginal walls, which is what keeps the tissue moist and pink. Healthy blood supply delivers oxygen and nutrients that maintain the surface layer of cells. As circulation decreases, the lining thins from many cell layers to just a few, and natural lubrication drops significantly. The vaginal environment shifts too: in reproductive years, vaginal pH stays at 4.5 or below, which is acidic enough to discourage infections. After menopause, pH can climb to 6 or even 7.5, making the tissue more vulnerable to bacterial and yeast overgrowth.
Menopause Is the Most Common Cause
The ovaries produce the majority of the body’s estrogen during reproductive years. At menopause, that production drops sharply and permanently. Unlike hot flashes, which tend to improve over time, vaginal atrophy typically gets worse the longer you go without estrogen. About 15% of women notice symptoms even before menopause, during the transitional years when hormone levels start to fluctuate. After menopause, the percentage with noticeable symptoms roughly triples.
The medical term for this condition has shifted in recent years. Clinicians now use “genitourinary syndrome of menopause” (GSM) to capture the full picture, since the same estrogen loss affects the vulva, urethra, and bladder alongside the vaginal canal. The name change reflects that this isn’t just about dryness. It can involve burning, irritation, urinary urgency, recurrent urinary tract infections, and pain during sex.
Cancer Treatments That Suppress Estrogen
Breast cancer therapies are a major non-menopausal cause. With roughly 3.8 million breast cancer survivors in the United States, this affects a significant number of women. Two main classes of drugs are responsible. Tamoxifen blocks estrogen from binding to breast tissue, but it can also reduce estrogen’s effects on vaginal cells. Aromatase inhibitors go further: they shut down estrogen production throughout the body, pushing estrogen levels even lower than typical menopause. Women on aromatase inhibitors often experience more severe vaginal atrophy than women who go through natural menopause, precisely because their estrogen levels are suppressed more aggressively.
Pelvic radiation therapy for cervical, uterine, or rectal cancers causes a different kind of damage. Radiation directly injures the vaginal lining, the small blood vessels supplying it, and the connective tissue beneath. This triggers local inflammation and cell death. With brachytherapy (radiation delivered internally), the damage tends to be distributed evenly throughout the vagina. External beam radiation may affect some areas more than others. The tissue changes from radiation can be permanent and compound any hormonal effects if the ovaries are also damaged or removed during treatment.
Chemotherapy and surgical removal of the ovaries can also trigger sudden menopause in younger women, bringing on atrophy years or decades earlier than expected.
Breastfeeding and Postpartum Hormonal Shifts
Many new mothers are surprised by vaginal dryness during breastfeeding. The cause is prolactin, the hormone that drives milk production. High prolactin levels suppress both estrogen and androgen production through a feedback loop in the brain. The result is a temporary hormonal state that mimics menopause: vaginal dryness, thinning tissue, pain during intercourse, and sometimes urinary symptoms. This resolves after weaning as prolactin drops and estrogen rebounds, but it can last the entire duration of breastfeeding, which for some women is a year or more.
Autoimmune Conditions
Sjögren’s syndrome, an autoimmune disease best known for causing dry eyes and dry mouth, also targets vaginal tissue. The mechanism is different from hormonal causes. In Sjögren’s, immune cells infiltrate the tissue just below the vaginal lining, concentrating in the layer closest to the surface. This immune attack damages the small blood vessels in the vaginal wall, reducing the number of smooth muscle cells that support healthy circulation. Women with Sjögren’s have measurably worse vaginal health scores, with tissue that is more fragile and prone to bleeding on contact. Because the underlying cause is immune-driven rather than hormonal, standard estrogen treatments may not fully resolve the problem.
Smoking and Estrogen Metabolism
Smoking accelerates estrogen breakdown in the liver. The effect is dose-dependent: the more you smoke and the longer you’ve smoked, the faster your body clears estrogen from circulation. This matters both before and after menopause. Before menopause, smoking can lower your baseline estrogen levels enough to bring on atrophy symptoms earlier. After menopause, if you’re using oral hormone therapy, smoking can reduce or completely cancel its effectiveness. The liver processes oral estrogen more rapidly in smokers, so the dose that would relieve symptoms in a nonsmoker may do little for someone who smokes heavily. This interaction has been demonstrated specifically with oral estrogen, not with patches or vaginal formulations that bypass the liver.
Other Contributing Factors
Several other situations lower estrogen enough to affect vaginal tissue. Surgical removal of both ovaries causes immediate menopause regardless of age. Certain medications used to treat endometriosis or uterine fibroids work by suppressing ovarian function, creating a temporary but sometimes prolonged low-estrogen state. Hypothalamic amenorrhea, which can result from excessive exercise, very low body weight, or extreme stress, shuts down the hormonal signaling chain that tells the ovaries to produce estrogen.
Age itself plays a role beyond just menopause. The longer tissues go without estrogen exposure, the more pronounced the changes become. A woman ten years past menopause will generally have more significant atrophy than someone one year past, even without any additional risk factors. This progressive nature is one reason the condition tends to worsen rather than stabilize over time, and why earlier intervention tends to be more effective than waiting.